Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Maxygen, Astellas to develop autoimmune disease and transplantation therapies
October 2008
SHARING OPTIONS:

REDWOOD CITY, Calif.Maxygen Inc. and Astellas Pharma Inc. in September announced an agreement to commercialize MAXY-4 lead candidates for autoimmune diseases and transplant rejection. Astellas has global rights to develop MAXY-4 candidates for transplant rejection and will cover those development costs. Maxygen, which has an option to co-promote any autoimmune products in North America, will receive a $10 million up-front payment and is eligible to receive up to $160 million in pre-launch milestone payments and tiered double-digit royalties on all sales. Astellas will pay for the first $10 million of certain preclinical costs, after which the companies will share preclinical and development costs of MAXY-4 candidates for autoimmune disease indications in North America and Europe. DDN

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.